Standard
264th ENMC International Workshop : Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th – 21st 2021. / Industry participants; Workshop Participants.
I:
Neuromuscular Disorders, Bind 32, Nr. 8, 2022, s. 697-705.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Industry participants & Workshop Participants 2022, '
264th ENMC International Workshop: Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th – 21st 2021',
Neuromuscular Disorders, bind 32, nr. 8, s. 697-705.
https://doi.org/10.1016/j.nmd.2022.06.005APA
Industry participants, & Workshop Participants (2022).
264th ENMC International Workshop: Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th – 21st 2021.
Neuromuscular Disorders,
32(8), 697-705.
https://doi.org/10.1016/j.nmd.2022.06.005Vancouver
Industry participants, Workshop Participants.
264th ENMC International Workshop: Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th – 21st 2021.
Neuromuscular Disorders. 2022;32(8):697-705.
https://doi.org/10.1016/j.nmd.2022.06.005Author
Industry participants ; Workshop Participants. / 264th ENMC International Workshop : Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th – 21st 2021. I: Neuromuscular Disorders. 2022 ; Bind 32, Nr. 8. s. 697-705.
Bibtex
@article{25e7cd6e1c1f495f9bd3ac3007bc0808,
title = "264th ENMC International Workshop: Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th – 21st 2021",
author = "Detering, {Nora Tula} and Alberto Zambon and Niko Hensel and Rashmi Kothary and Kathryn Swoboda and Gillingwater, {Thomas H.} and Giovanni Baranello and John Vissing and {Industry participants} and {Workshop Participants}",
note = "Funding Information: GB has received speaker and consulting fees from Biogen, Novartis Gene Therapies, Inc. (AveXis), and Roche and has worked as principal investigator of SMA studies sponsored by Novartis Gene Therapies, Inc., and Roche. The other organizers do not have conflicts to declare for this specific workshop.We acknowledge especially the staff of the European Neuromuscular Center (ENMC) Alexandra Breukel, Managing Director and Annelies Zittersteijn, Operational Manager. This Workshop was made possible thanks to the financial support of the ENMC and ENMC main sponsors: Association Fran{\c c}aise contre les Myopathies (France), Deutsche Gesellschaft f{\"u}r Muskelkranke (Germany), Muscular Dystrophy Campaign (UK), Muskelsvindfonden (Denmark), Prinses Beatrix Spierfonds (The Netherlands), Schweizerische Stiftung f{\"u}r die Erforschung der Muskelkrankheiten (Switzerland), Telethon Foundation (Italy), Spierziekten Nederland (The Netherlands) and the associated members: Finnish Neuromuscular Association (Finland) and {\"O}sterreichische Muskelforschung (Austria). The ENMC acknowledges the support of MDA USA and SMA Europe. Special thanks to the members of the ENMC Company Forum: Amicus Therapeutics, AveXis, Biogen, CSL Behring, Ionis Pharmaceuticals, PerkinElmer, Roche, Sanofi Genzyme, Sanquin Plasma Products, Santhera Pharmaceuticals, and other involved partner organizations for their support of the ENMC workshops. We thank SMA Europe and Cure SMA for the support provided. We acknowledge GB, PC, TG, ET, LvdP, BW have received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska-Curie Actions (MSCA) grant agreement SMABEYOND No 956185. Funding Information: We acknowledge especially the staff of the European Neuromuscular Center (ENMC) Alexandra Breukel, Managing Director and Annelies Zittersteijn, Operational Manager. This Workshop was made possible thanks to the financial support of the ENMC and ENMC main sponsors: Association Fran{\c c}aise contre les Myopathies (France), Deutsche Gesellschaft f{\"u}r Muskelkranke (Germany), Muscular Dystrophy Campaign (UK), Muskelsvindfonden (Denmark), Prinses Beatrix Spierfonds (The Netherlands), Schweizerische Stiftung f{\"u}r die Erforschung der Muskelkrankheiten (Switzerland), Telethon Foundation (Italy), Spierziekten Nederland (The Netherlands) and the associated members: Finnish Neuromuscular Association (Finland) and {\"O}sterreichische Muskelforschung (Austria). The ENMC acknowledges the support of MDA USA and SMA Europe. Special thanks to the members of the ENMC Company Forum: Amicus Therapeutics, AveXis, Biogen, CSL Behring, Ionis Pharmaceuticals, PerkinElmer, Roche, Sanofi Genzyme, Sanquin Plasma Products, Santhera Pharmaceuticals, and other involved partner organizations for their support of the ENMC workshops. We thank SMA Europe and Cure SMA for the support provided. We acknowledge GB, PC, TG, ET, LvdP, BW have received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska-Curie Actions (MSCA) grant agreement SMABEYOND No 956185 .",
year = "2022",
doi = "10.1016/j.nmd.2022.06.005",
language = "English",
volume = "32",
pages = "697--705",
journal = "Journal of Neuromuscular Diseases",
issn = "0960-8966",
publisher = "Elsevier",
number = "8",
}
RIS
TY - JOUR
T1 - 264th ENMC International Workshop
T2 - Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th – 21st 2021
AU - Detering, Nora Tula
AU - Zambon, Alberto
AU - Hensel, Niko
AU - Kothary, Rashmi
AU - Swoboda, Kathryn
AU - Gillingwater, Thomas H.
AU - Baranello, Giovanni
AU - Vissing, John
AU - Industry participants
AU - Workshop Participants
N1 - Funding Information:
GB has received speaker and consulting fees from Biogen, Novartis Gene Therapies, Inc. (AveXis), and Roche and has worked as principal investigator of SMA studies sponsored by Novartis Gene Therapies, Inc., and Roche. The other organizers do not have conflicts to declare for this specific workshop.We acknowledge especially the staff of the European Neuromuscular Center (ENMC) Alexandra Breukel, Managing Director and Annelies Zittersteijn, Operational Manager. This Workshop was made possible thanks to the financial support of the ENMC and ENMC main sponsors: Association Française contre les Myopathies (France), Deutsche Gesellschaft für Muskelkranke (Germany), Muscular Dystrophy Campaign (UK), Muskelsvindfonden (Denmark), Prinses Beatrix Spierfonds (The Netherlands), Schweizerische Stiftung für die Erforschung der Muskelkrankheiten (Switzerland), Telethon Foundation (Italy), Spierziekten Nederland (The Netherlands) and the associated members: Finnish Neuromuscular Association (Finland) and Österreichische Muskelforschung (Austria). The ENMC acknowledges the support of MDA USA and SMA Europe. Special thanks to the members of the ENMC Company Forum: Amicus Therapeutics, AveXis, Biogen, CSL Behring, Ionis Pharmaceuticals, PerkinElmer, Roche, Sanofi Genzyme, Sanquin Plasma Products, Santhera Pharmaceuticals, and other involved partner organizations for their support of the ENMC workshops. We thank SMA Europe and Cure SMA for the support provided. We acknowledge GB, PC, TG, ET, LvdP, BW have received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions (MSCA) grant agreement SMABEYOND No 956185.
Funding Information:
We acknowledge especially the staff of the European Neuromuscular Center (ENMC) Alexandra Breukel, Managing Director and Annelies Zittersteijn, Operational Manager. This Workshop was made possible thanks to the financial support of the ENMC and ENMC main sponsors: Association Française contre les Myopathies (France), Deutsche Gesellschaft für Muskelkranke (Germany), Muscular Dystrophy Campaign (UK), Muskelsvindfonden (Denmark), Prinses Beatrix Spierfonds (The Netherlands), Schweizerische Stiftung für die Erforschung der Muskelkrankheiten (Switzerland), Telethon Foundation (Italy), Spierziekten Nederland (The Netherlands) and the associated members: Finnish Neuromuscular Association (Finland) and Österreichische Muskelforschung (Austria). The ENMC acknowledges the support of MDA USA and SMA Europe. Special thanks to the members of the ENMC Company Forum: Amicus Therapeutics, AveXis, Biogen, CSL Behring, Ionis Pharmaceuticals, PerkinElmer, Roche, Sanofi Genzyme, Sanquin Plasma Products, Santhera Pharmaceuticals, and other involved partner organizations for their support of the ENMC workshops. We thank SMA Europe and Cure SMA for the support provided. We acknowledge GB, PC, TG, ET, LvdP, BW have received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions (MSCA) grant agreement SMABEYOND No 956185 .
PY - 2022
Y1 - 2022
U2 - 10.1016/j.nmd.2022.06.005
DO - 10.1016/j.nmd.2022.06.005
M3 - Journal article
C2 - 35794048
AN - SCOPUS:85133386413
VL - 32
SP - 697
EP - 705
JO - Journal of Neuromuscular Diseases
JF - Journal of Neuromuscular Diseases
SN - 0960-8966
IS - 8
ER -
